Cyclerion therapeutics, inc. (CYCN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Revenue from related party

1,014

-

1,398

1,628

-

-

-

-

-

Cost and expenses:
Research and development

16,825

20,682

22,295

25,759

26,404

22,452

21,499

22,251

21,514

General and administrative

6,891

7,385

7,119

8,923

10,977

8,450

7,787

7,530

3,769

Gain on lease modification

2,113

-

-

-

-

-

-

-

-

Total cost and expenses

21,603

28,067

29,414

34,682

37,381

30,902

29,286

29,781

25,283

Loss from operations

-20,589

-26,586

-28,016

-33,054

-37,381

-30,902

-29,286

-29,781

-25,283

Interest and other income

361

-

699

800

-

-

-

-

-

Net loss

-20,228

-26,056

-27,317

-32,254

-37,381

-30,902

-29,286

-29,781

-25,283

Net loss per share:
Basic and diluted net loss per share (in dollars per share)

-0.73

-0.94

-1.00

-1.18

-1.37

-

-1.07

-1.09

-

Weighted average shares used in calculating:
Basic and diluted net loss per share (in shares)

27

27

27

27

27

-

27

27

-

Other comprehensive loss:
Net loss

-20,228

-26,056

-27,317

-32,254

-37,381

-

-29,286

-29,781

-

Other comprehensive loss:
Foreign currency translation adjustment

2

-

1

-4

-

-

-

-

-

Total other comprehensive loss

2

-

1

-4

-

-

-

-

-

Comprehensive loss

-20,226

-26,073

-27,316

-32,258

-37,381

-

-29,286

-29,781

-